Treatment of Ewing sarcoma family of tumors: current status and outlook for the future
C Rodriguez‐Galindo, SL Spunt… - Medical and pediatric …, 2003 - Wiley Online Library
Abstract Background The Ewing sarcoma family of tumors (ESFT) comprises a group of well‐
characterized neoplasms with aggressive behavior. Despite significant progress with the …
characterized neoplasms with aggressive behavior. Despite significant progress with the …
Ewing's sarcoma: standard and experimental treatment options
Opinion statement Ewing sarcoma family tumors (EWS), which include classic Ewing's
sarcoma in addition to primitive neuroectodermal tumor and Askin tumor, are the second …
sarcoma in addition to primitive neuroectodermal tumor and Askin tumor, are the second …
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
E De Alava, A Kawai, JH Healey, I Fligman… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE More than 90% of Ewing's sarcomas (ES) contain a fusion of the EWS and FLI1
genes, due to the t (11; 22)(q24; q12) translocation. At the molecular level, the EWS-FLI1 …
genes, due to the t (11; 22)(q24; q12) translocation. At the molecular level, the EWS-FLI1 …
Additive manufacturing of hydrogel-based materials for next-generation implantable medical devices
Implantable microdevices often have static components rather than moving parts and exhibit
limited biocompatibility. This paper demonstrates a fast manufacturing method that can …
limited biocompatibility. This paper demonstrates a fast manufacturing method that can …
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue …
FC Eilber, G Rosen, J Eckardt, C Forscher… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To determine whether treatment-induced pathologic necrosis correlates with
local recurrence and overall survival in patients who receive neoadjuvant therapy for high …
local recurrence and overall survival in patients who receive neoadjuvant therapy for high …
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli
G Bacci, S Ferrari, F Bertoni, S Rimondini… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: The identification of prognostic factors in patients with nonmetastatic Ewing's
sarcoma could allow the use of risk-adapted therapeutic strategies of treatment. PATIENTS …
sarcoma could allow the use of risk-adapted therapeutic strategies of treatment. PATIENTS …
Ewing Sarcomas With p53 Mutation or p16/p14ARF Homozygous Deletion: A Highly Lethal Subset Associated With Poor Chemoresponse
HY Huang, PB Illei, Z Zhao, M Mazumdar… - Journal of clinical …, 2005 - ascopubs.org
Purpose EWS-FLI1 fusion type, p53 mutation, and homozygous deletion of p16/p14ARF
have each been shown to be prognostically significant in Ewing sarcoma (ES). We provide …
have each been shown to be prognostically significant in Ewing sarcoma (ES). We provide …
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue …
V Evilevitch, WA Weber, WD Tap… - Clinical Cancer …, 2008 - AACR
Purpose: Change in tumor size as classified by Response Evaluation Criteria in Solid
Tumors poorly correlates with histopathologic response to neoadjuvant therapy in patients …
Tumors poorly correlates with histopathologic response to neoadjuvant therapy in patients …
Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between …
G Bacci, C Forni, A Longhi, S Ferrari, D Donati… - European Journal of …, 2004 - Elsevier
We evaluated the long-term results obtained in 402 patients with non-metastatic Ewing's
sarcoma (ES) of the bone treated in a single institution with adjuvant and neoadjuvant …
sarcoma (ES) of the bone treated in a single institution with adjuvant and neoadjuvant …
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance
TP Robin, A Smith, E McKinsey, L Reaves… - Molecular Cancer …, 2012 - AACR
Ewing sarcoma is an aggressive pediatric cancer of the bone and soft tissue, in which
patients whose tumors have a poor histologic response to initial chemotherapy have a poor …
patients whose tumors have a poor histologic response to initial chemotherapy have a poor …